EMCURE
Emcure Pharmaceuticals Limited
Each stock's 10,000-path forecast, rendered as light.
Emcure Pharmaceuticals Limited (EMCURE) Stock Analysis & Case Study
Is EMCURE a good buy? The data-driven verdict.
Emcure Pharmaceuticals Limited (EMCURE) trades at ₹1,978,on the numbers it worth a closer look, a Downstox Snapshot Score of 58/100.
On the numbers, Emcure Pharmaceuticals Limited (EMCURE) worth a closer look, a Downstox Snapshot Score of 58/100, weighing premium at 36.4× earnings, ROE of 20.1%, a 56% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
EMCURE fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How EMCURE ranks against the 2,373 companies in our screener
- EMCURE's market cap of 37,526 Cr ranks in the 90th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- EMCURE's book value of ₹261 ranks in the 78th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- EMCURE's promoter holding of 77.8% ranks in the top 3% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- EMCURE's 3-year profit (PAT) growth of 21.0% ranks in the 58th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- EMCURE's 3-year revenue growth of 15.0% ranks in the 63rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- EMCURE's debt-to-equity ratio of 0.31x is lower than 50% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is EMCURE overvalued? EMCURE P/E vs peers
EMCURE trades at 36.4× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
EMCURE share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.1y of EMCURE history (18%/yr drift, 36%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| EMCURE 2027 | ₹1,307 | ₹2,076 | ₹3,297 | +5% |
| EMCURE 2028 | ₹1,121 | ₹2,178 | ₹4,233 | +10% |
| EMCURE 2029 | ₹1,011 | ₹2,286 | ₹5,166 | +16% |
| EMCURE 2030 | ₹942 | ₹2,398 | ₹6,103 | +21% |
| EMCURE 2031 | ₹898 | ₹2,516 | ₹7,049 | +27% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability EMCURE goes up, or doubles?
The bull case for EMCURE
- EMCURE's return on equity of 20.1% ranks in the 84th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- EMCURE's return on capital employed of 24.0% ranks in the 87th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹5,166.
The bear case & risks
- EMCURE's P/E of 36.4x is lower than 37% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹1,011.
EMCURE volatility & expected range, how bumpy is the ride?
Over the last 2.1 years EMCURE compounded at 18%/year with annualized volatility of 36%. That volatility implies a 1-year 80% range of ₹1,307-₹3,297, the honest backbone behind any single price target.
EMCURE price forecast, the full 60-month probability fan
EMCURE price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds EMCURE hits common targets within the simulated horizon?
Full multi-horizon detail on the EMCURE price target & forecast page.
EMCURE Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. EMCURE scores 6/8, mixed financial health.
EMCURE MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy EMCURE with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 30.73% | 3.3× |
| ZerodhaCHEAPEST | 30.73% | 3.3× |
| Groww | 30.85% | 3.2× |
| Dhan | 30.73% | 3.3× |
| Kotak Neo | 30.77% | 3.2× |
| Paytm Money | 30.91% | 3.2× |
| Pocketful | 30.86% | 3.2× |
| Anand RathiCHEAPEST | 30.73% | 3.3× |
| Bajaj Broking | 32.00% | 3.1× |
| Share India | 30.82% | 3.2× |
Compare every broker on the EMCURE MTF page.
About Emcure Pharmaceuticals Limited: sector, index & market-cap context
Emcure Pharmaceuticals Limited (EMCURE) is a mid-cap NSE-listed company, and a constituent of the Nifty 500 index, with a market capitalisation of ₹37,526 Cr. See more stocks on our screener.
How the EMCURE Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Emcure Pharmaceuticals Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
EMCURE analysis, FAQs
Is Emcure Pharmaceuticals Limited (EMCURE) a good buy?
On the numbers, Emcure Pharmaceuticals Limited (EMCURE) worth a closer look, a Downstox Snapshot Score of 58/100, weighing premium at 36.4× earnings, ROE of 20.1%, a 56% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is EMCURE overvalued or undervalued?
EMCURE trades at 36.4× earnings, premium versus the ~22× long-run Nifty average.
What is the EMCURE share price target for 2031?
EMCURE's probability-weighted 2031 median target is ₹2,516, with an 80% range of ₹898-₹7,049 (10,000-path Monte-Carlo).
What is the probability EMCURE doubles in 5 years?
The modelled probability of EMCURE reaching ₹3,957 (2×) within 5 years is 29%.
What is the bull case for EMCURE?
EMCURE's return on equity of 20.1% ranks in the 84th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. EMCURE's return on capital employed of 24.0% ranks in the 87th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in EMCURE?
EMCURE's P/E of 36.4x is lower than 37% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.